Recruiting
Phase 1
Phase 2

TSHA-105

Sponsor:

TESS Research Foundation

Code:

NCT07102524

Conditions

SLC13A5 Citrate Transporter Disorder

Eligibility Criteria

Sex: All

Age: 2 - 20

Healthy Volunteers: Not accepted

Interventions

TSHA-105

Study Details

Brief summary:

Phase 1/2, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of TSHA-105 in individuals with SLC13A5 Citrate Transporter Disorder

Conditions

SLC13A5 Citrate Transporter Disorder

Study ID

NCT07102524

Start date

Jul 15, 2026

Status verified date

Jun, 2026

Completion date

Jun 1, 2031

Anticipated

Primary completion date

Dec 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 2 - 20

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male and females between the ages of 2 to 9 or 10 to 20 years at the time of screening
  • Confirmed diagnosis of SLC13A5 citrate transporter disorder by genomic DNA mutation analysis (confirmed by a CLIA certified, CE-marked, or equivalent lab) demonstrating homozygous or compound heterozygous, confirmed pathogenic or likely pathogenic variants in the SLC13A5 gene
  • Clinical features consistent with SLC13A5 citrate transporter disorder
  • Written informed consent provided by subject/parent/guardian and willingness to participate and comply with all the study related visits and procedures. Assent provided by children 10 to 17 years old based on their ability to understand the risks and possible benefits, and the activities expected of them.
  • Subjects able to reproduce must use a barrier method of contraception for the first 12 months after dosing as well as at least one additional highly effective birth control method if sexually active

Exclusion Criteria:

  • Inability to participate in study procedures (as determined by the site investigator)
  • Presence of a concomitant medical condition that precludes lumbar puncture (LP) or use of anesthetics
  • History of bleeding disorder or any other medical condition or circumstance in which lumbar puncture is contraindicated according to local institutional policy
  • Inability to be safely sedated in the opinion of the clinical anesthesiologist
  • Active infection, at the time of dosing, based on clinical observations
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
  • Inability of the subject to undergo MRI according to local institutional policy
  • Inability of the subject to undergo any other procedure required in this study
  • The presence of significant non-SLC13A5 related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study
  • Have received an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.
  • Enrollment and participation in another interventional clinical trial
  • Contraindication to TSHA-105 or any of its ingredients
  • Contraindication to any of the immune suppression medications used in this study
  • Clinically significant abnormal laboratory values (hemoglobin < 6 or > 20 g/dL; white blood cell > 20,000 per cmm, platelets count < 100,000 per cmm; INR > ULN; GGT, ALT, and AST or total bilirubin > 2x ULN, creatinine ≥ 1.5 mg/dL) prior to gene replacement therapy

Study Design

Enrollment

8 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: TSHA-105 treament

TSHA-105 Treatment

Interventions

TSHA-105

AAV9/SLC13A5

Primary outcome measure

  • Safety and Tolerability [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Alexandria Silver, RN

214-456-0876Alexandria.Silver@UTSouthwestern.edu

Holly Lawrence

Holly.Lawrence@UTSouthwestern.edu

Locations

University of Texas Southwestern Medical Center

Recruiting

Dallas, Texas, United States, 75390-7208

Contacts

Alexandria Silver, RN

214-456-0876Alexandria.Silver@UTSouthwestern.edu

Principal Investigator:

Dallas Armstrong, MD

More Information

Sponsor

TESS Research Foundation

Last update posted

Jun 30, 2026

Last verified

Jun, 2026

Keywords

  • SLC13A5
  • AAV9
  • Epileptic Encephalopathy
  • SLC13A5 Deficiency
  • SLC13A5 Citrate Transporter Disorder

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by TESS Research Foundation on 2026-06-30.